DarioHealth (NASDAQ:DRIO) Price Target Cut to $5.00 by Analysts at Stifel Nicolaus

DarioHealth (NASDAQ:DRIO) had its price objective cut by equities researchers at Stifel Nicolaus to $5.00 in a report released on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus‘s price objective would indicate a potential upside of 203.03% from the stock’s previous close.

Several other research analysts have also weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DarioHealth in a research report on Tuesday, October 6th. Alliance Global Partners assumed coverage on DarioHealth in a research report on Wednesday, August 19th. They issued a “buy” rating and a $12.00 target price on the stock. TD Cowen cut their target price on DarioHealth from $11.00 to $8.00 and set a “hold” rating on the stock in a research report on Wednesday, August 12th. Finally, BTIG Research assumed coverage on DarioHealth in a research report on Tuesday, October 27th. They issued a “buy” rating and a $6.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, DarioHealth presently has an average rating of “Hold” and an average price target of $7.75.

DarioHealth Trading Down 22.5%

Shares of DarioHealth stock opened at $1.65 on Friday. The company has a quick ratio of 1.92, a current ratio of 2.31 and a debt-to-equity ratio of 0.56. The firm has a market cap of $16.17 million, a PE ratio of -0.27 and a beta of 1.18. The business’s fifty day moving average is $5.15 and its two-hundred day moving average is $7.37. DarioHealth has a fifty-two week low of $1.45 and a fifty-two week high of $14.77.

DarioHealth (NASDAQ:DRIO) last issued its earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.22. The business had revenue of $5.31 million for the quarter, compared to analyst estimates of $5.21 million. DarioHealth had a negative return on equity of 54.81% and a negative net margin of 169.87%. Analysts anticipate that DarioHealth will post -2.94 earnings per share for the current year.

Institutional Trading of DarioHealth

Large investors have recently added to or reduced their stakes in the stock. Commonwealth Equity Services LLC acquired a new stake in DarioHealth in the 3rd quarter valued at $159,000. BlackRock Inc. acquired a new stake in shares of DarioHealth during the second quarter valued at about $249,000. Finally, Nantahala Capital Management LLC acquired a new stake in shares of DarioHealth during the second quarter valued at about $4,030,561. 33.39% of the stock is currently owned by institutional investors and hedge funds.

DarioHealth News Summary

These are some of the DRIO news items that stood out recently:

• Positive Sentiment: Q3 revenue rose 6% year over year and 3% sequentially to $5.3 million. The company said its operating loss fell 15% and operating expenses declined 10%; its quarterly loss also beat analyst estimates and narrowed substantially from a year earlier. DarioHealth Q3 financial results
• Positive Sentiment: DarioHealth signed a New Jersey health plan covering 1.5 million lives and is working with a national health-plan customer on GLP-1 therapy delivery. It reported more than 180 signed accounts and $13.1 million in contracted and late-stage ARR, over 80% tied to multi-condition opportunities. Cash and short-term deposits totaled $31.2 million at quarter-end. Q3 financial results and business update
• Neutral Sentiment: Stifel Nicolaus kept a “buy” rating but cut its price target from $10 to $5. The revised target still implies substantial upside from the cited $1.65 share price, but the reduction signals a more cautious valuation outlook.

About DarioHealth

DarioHealth Corp. is a digital health company that develops technology-enabled solutions for managing chronic conditions. Its platform combines connected medical devices, mobile applications, data analytics and personalized coaching to help individuals monitor and improve their health. The company’s offerings have focused on conditions including diabetes, hypertension, musculoskeletal disorders and behavioral health. Products and services may include connected blood glucose and blood pressure monitoring, digital programs for pain and mobility management, health coaching, educational content and tools that support healthier daily habits.